Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 4, July-August, p. 481–487

Publication type: original article

Language: English

Comparison of Topical Sucralfate and Silver Sulfadiazine Cream in Second Degree Burns in Rats

Porównanie skuteczności miejscowego sukralfatu i soli srebrowej sulfadiazyny w kremie w leczeniu oparzeń drugiego stopnia u szczurów

Akram Beheshti1,A,B,E, Younes Shafigh1,B,E, Amir-abdollah Zangivand1,C,D,E,F, Fatemeh Samiee-Rad1,C,D,E,F, Gholamreza Hassanzadeh1,B,C, Navid Shafigh1,B,G

1 Qazvin University of Medical Sciences, Iran

Streszczenie

Wprowadzenie.Najbardziej rozpowszechnionym sposobem miejscowego leczenia oparzeń II stopnia jest sól srebrowa sulfadiazyny 1% (SSD). Ostatnie badania wykazały, że leczenie oparzeń II stopnia jest opóźnione z wykorzystaniem SSD. Jednym z możliwych opatrunków oparzeniowych jest sukralfat.
Cel pracy. Analiza porównawcza wpływu sukralfatu i SSD na oparzenia drugiego stopnia u szczurów.
Materiał i metody. Czterdzieści osiem samców szczurów podzielono na trzy równe grupy. Model oparzenia utworzono na grzbiecie wszystkich szczurów. Spalone obszary w grupach pierwszej, drugiej i trzeciej codziennie pokrywano odpowiednio sukralfatem, SSD i zimną śmietaną (grupa kontrolna). Na koniec dnia 7, 14, 21 i 28 szczury usypiano i spalone próbki tkanki skóry zebrano do badań histopatologicznych.
Wyniki. Na koniec badania naskórek i warstwa rogowa skóry były całkowicie uformowane w grupie SSD i sukralfatu, jednak skóra właściwa została wytworzona w grupie z sukralfatem. Skuteczność gojenia ran obliczono na 76%, 91% i 100% w grupie kontrolnej, z solą srebrową sulfadiazyny i z sukralfatem.
Wnioski. Sukralfat wywiera korzystny wpływ na gojenie ran. Przy zastosowaniu miejscowym sukralfat przyspieszał proces gojenia ran po oparzeniu w porównaniu z grupą kontrolną i SSD oraz może być stosowany jako alternatywa lub środek wspomagający leczenie w przyszłości.

Key words

sucralfate, silver sulfadiazine, second degree burns, rat.

Słowa kluczowe

sukralfat, sól srebrowa sulfadiazyny, drugi stopień oparzenia, szczur.

References (42)

  1. Demling RH: Burns and other thermal injuries. In: Current surgical diagnosis and treatment. eds.: lawrence W, Gerard M. lang Medical Books/McGraw-Hill, 2002, 267–281.
  2. Wilkinson E: The epidemiology of burns in secondary care, in a population of 2.6 million people. Burns 1998, 24, 139–143.
  3. Taddonio TE, Thomson PD, Smith DJ, Prasad JK: A survey of wound monitoring and topical antimicrobial therapy practices in the treatment of burn injury. J Burn Care Rehabil 1990, 11, 423–427.
  4. Gracia CG: An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns 2001, 27, 67–74.
  5. Gregory RS, Piccolo N, Piccolo MT, Piccolo MS, Heggers JP: Comparison of propolis skin cream to silver sulfadiazine: A naturopathic alternative to antibiotics in treatment of minor burns. J Altern Complementary Med 2002, 8, 77–83.
  6. Hosnuter M, Gurel A, Bauccu O, Armutcu F, Kargi E, Isikdemir A: The effect of CAPe on lipid peroxidation and nitric oxide levels in the plasma of rats following thermal injury. Burns 2004, 30, 121–125.
  7. Lee AR, Moon HK: effect of topically applied silver sulfadiazine on fibroblast cell proliferation and biomechanical properties of the wound. Arch Pharm Res 2003, 26, 855–860.
  8. Stern HS: Silver sulphadiazine and the healing of partial thickness burns: a prospective clinical trail. Br J Plast Surg 1989, 42, 581–585.
  9. Hayashi AH, Lau HY and Gillis DA: Topical sucralfate: effective therapy for the management of resistant peristomal and perineal excoriation. J Pediatr Surg 1991, 26, 1279–1281.
  10. Lyon CC, Stapleton M, Smith AJ, Griffiths CE, Beck MH: Topical sucralfate in the management of peristomal skin disease: an open study. Clin exp Dermatol 2000, 25, 584–588.
  11. Delaney G, Fisher R, Hook C, Barton M: Sucralfate cream in the management of moist desquamation during radiotherapy. Australas Radiol 1997, 41, 270–275.
  12. Maiche A, Isokangas OP, Grohn P: Skin protection by sucralfate cream during electron beam therapy. Acta Oncol 1994, 33, 201–203.
  13. Markham T, Kennedy F, Collins P: Topical sucralfate for erosive irritant diaper dermatitis. Arch Dermatol 2000, 136, 1199–1200.
  14. Lentz SS, Barrett RJ, Homesley HD: Topical sucralfate in the treatment of vaginal ulceration. Obstet Gynecol 1993, 81, 869–871.
  15. Marini I, Vecchiet F: Sucralfate: a help during oral management in patients with epidermolysis bullosa. J Periodontol 2001, 72, 691–695.
  16. Banati A, Chowdhury SR, Mazumder S: Topical use of Sucralfate Cream in second and third degree burns. Burns 2001, 27, 465–469.
  17. Tumino G, Masuelli L, Bei R, Simonelli L, Santoro A, Francipane S: Topical treatment of chronic venous ulcers with sucralfate: a placebo controlled randomized study. Int J Mol Med 2008, 22, 17–23.
  18. Tryba M, Mantey-Stiers F: Antibacterial activity of sucralfate in human gastric juice. Am J Med 1987, 83, 125–127.
  19. Kawazoe, H, Takaoka K., Shibata H, Arakaki N, Higuti T, Negayama K, Houchi H, Tsuchiya K, Takiguchi Y: Comparison of antibacterial activity of fluoroquinolones with their sucralfate-complexes against clinically-isolated bacteria. J Health Sci 2009, 55, 790–795.
  20. Gupta PJ, Heda PS, Kalaskar S, Tamaskar VP: Topical sucralfate decreases pain after hemorrhoidectomy and improves healing: a randomized, blinded, controlled study. Dis Colon Rectum 2008, 51, 231–234.
  21. Durmus AS, Han MC, Yaman I: Comparative evaluation of Collagenase and Silver Sulfadiazine on Burned Wound Healing in Rats. F Ü Sağ Bil Vet Derg 2009, 23, 135–139.
  22. Shahabi S, Hashemi S, Shahrokhi S, et al.: Hyperthermia can accelerate the healing process of 2nd degree burn wounds. J Kerman Univ Med Sci 2005, 3, 110–118.
  23. Eming SA, Krieg T, Davidson JM: Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007, 127, 514–525.
  24. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003, 83, 835–870.
  25. Roy H, Bhardwaj S, Yla-Herttuala S: Biology of vascular endothelial growth factors. FeBS lett 2006, 580, 2879–2887.
  26. Neal MS: Angiogenesis: is it the key to controlling the healing process? J Wound Care 2001, 10, 281–287.
  27. Hu YL, Guo SZ, Yan PS: effect of local application of basic fibroblast growth factor and sucralfate on skin tissue structure after expansion. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2002, 16, 340–344.
  28. Burch RM, McMillan BA: Sucralfate induces proliferation of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full-thickness skin wounds. Agents Actions 1991, 34, 229–231.
  29. Candelli M, Carloni E, Armuzzi A, Cammarota G, Ojetti V, Pignataro G, Santoliquido A, Pola R, Pola E, Gasbarrini G, Gasbarrini A: Role of sucralfate in gastrointestinal diseases. Panminerva Med 2000, 42, 55–59.
  30. Hollander D, Tarnawski A, Krause WJ, Gergely H: Protective effect of sucralfate against alcohol-induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastructural, and functional time sequence analysis. Gastroenterology 1985, 88, 366–374.
  31. Gupta PJ, Heda PS, Shrirao SA, Kalaskar SS: Topical sucralfate treatment of anal fistulotomy wounds: a randomized placebo-controlled trial. Dis Colon Rectum 2011, 54, 699–704.
  32. Konturek SJ, Konturek JE, Brzozowski T, et al.: effect of sucralfate on growth factor availability. In: Sucralfate: From Basic Science to the Bedside. Hollander D and Tytgat GNJ (eds). Plenum Medical Book Co., New York 1993, 175–189.
  33. Folkmann J, Szabo S, Stovroff M: Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991, 214, 414–426.
  34. Szabo S, Vattay P, Scarbrough E, Folkman J: Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. Am J Med 1991, 91, 158–160.
  35. McCarthy DM: Sucralfate. N engl J Med 1991, 325, 1017–1025.
  36. Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M: Randomized, double-blind, placebo-controlled, doseranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers. Wound Rep Reg 1999, 7, 17–25.
  37. Sweetman SC (ed): Sucralfate. In: Martindale: The Complete Drug Reference. 33rd edition, The Pharmaceutical Press, london 2002, 1250–1251.
  38. Wang X, Kimble RM: A review on porcine burn and scar models and their relevance to humans. Wound Pract Res 2010, 18, 41–49.
  39. Nexø E, Poulsen SS: Does epidermal growth factor play a role in the action of sucralfate? Scand J Gasteroenterol 1987, 125, 45–49.
  40. Mannari C, Santi S, Migliori M, Filippi C, Origlia N, Sansò M, Boldrini E, Giovannini L: Sucralfate modulates uPAR and eGFR expression in an experimental rat model of cervicitis. Int J Immunopathol Pharmacol 2008, 21, 651–658.
  41. Allain P, Mauras Y, Krari N, Duchier J, Cournot A, Larcheveque J: Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate. Br J Clin Pharm 1990, 29, 391–395.
  42. Fischer RS: Sucralfate a review of drug tolerance and safety, J Clin Gastroenterol 1981, Suppl. 2, 181–184.
© Wroclaw Medical University